|Mr. Steven Adam Lisi||CEO & Chairman||450k||N/A||1971|
|Mr. Amir Avniel||Co-Founder, Pres, COO & Director||400k||N/A||1974|
|Mr. Douglas Quinton Larson||CFO, Principal Financial Officer & Principal Accounting Officer||N/A||N/A||1971|
|Ms. Maria Yonkoski||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Adam Newman||Chief Legal Officer & Gen. Counsel||N/A||N/A||N/A|
|Ms. Rebecca Van Doren||Head of Sales||N/A||N/A||N/A|
|Ms. Kori-Ann Taylor||Head of Marketing||N/A||N/A||N/A|
|Prof. Andrew R. Colin M.D.||Chief Medical Officer & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Giora Davidai M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Duncan Fatkin||Chief Commercial Officer||N/A||N/A||N/A|
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Beyond Air, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.